Fred Aslan

Fred Aslan is a seasoned executive in the biotech and healthcare sectors, currently serving as President and Chief Executive Officer of Artiva Biotherapeutics since January 2021, focusing on innovative cellular immunotherapies for cancer treatment. As the founder and advisor of Vyttra Diagnósticos, the largest in-vitro diagnostics company in Brazil, Fred has played a pivotal role in its establishment and growth. Additionally, Fred is the founder and Executive Chairman of VYDENCE Medical, which leads the Brazilian market in dermatology-focused medical devices. Previous experience includes leadership positions at Vividion Therapeutics and Venrock, along with a background in business development at CuraGen Corporation and strategic consulting at The Boston Consulting Group. Fred holds an MBA from Harvard Business School, an MD from Yale University, and a BS in Biology from Duke University.